#Taiwan #Tainan #Energenesis #ENERGI #Space Anemia

Energenesis Biomedical's ENERGI Approach to Space Anemia

Energenesis Biomedical made a significant mark at TASTI 2026, presenting their innovative strategies aimed at combating Space Anemia. The presentation, titled "ATP: Powering Human Health Beyond Earth," emphasized the growing importance of addressing health issues faced by astronauts on prolonged missions into space.

The Challenge of Space Anemia

As space travel becomes increasingly feasible, the biological challenges posed by microgravity are coming into sharper focus. Recent studies indicate that astronauts experience accelerated red blood cell destruction when in orbit—up to 54% more than on Earth. This condition, known as Space Anemia, raises significant concerns about the long-term health and performance of astronauts in deep-space missions.

In light of this, Energenesis Biomedical aims to develop a solution that not only addresses Space Anemia but also contributes to the health and safety of astronauts. Dr. Han-Min Chen, Chairman and CEO of Energenesis, highlighted the need for innovative approaches to maintain cellular energy in the face of microgravity, radiation, and disrupted circadian rhythms, all of which can severely impact various bodily functions, including the immune system and cardiovascular health.

The ENERGI Solution

At the heart of Energenesis' strategy lies the proprietary ENERGI platform, designed to enhance cellular energy by increasing ATP (adenosine triphosphate) levels. By elevating ATP, the fundamental energy currency of cells, ENERGI aims to improve the resilience and stability of red blood cells under extreme space conditions. Experimental data presented at TASTI 2026 indicates promising results, showing that higher ATP levels lead to improved red blood cell endurance and function.

"Astronauts depend on their cells having enough energy to stay healthy on long missions," Dr. Chen remarked. This research into Space Anemia is a natural extension of Energenesis’ ongoing work focused on cellular energy restoration.

Broader Implications for Health on Earth

Interestingly, the research on Space Anemia could provide insights beneficial to many individuals on Earth. Conditions that lead to red blood cell loss, such as prolonged bed rest, aging, or critical illness, could potentially benefit from the ENERGI approach. The emphasis on cellular repair and energy restoration could provide new avenues for treatment and prevention strategies in clinical medicine.

About Energenesis Biomedical

Energenesis Biomedical Co., Ltd., listed on TWSE as 6657, is a clinical-stage biopharmaceutical company devoted to restoring cellular energy and activating the body's intrinsic repair mechanisms. Combining cutting-edge small-molecule research with artificial intelligence tools, Energenesis focuses on developing therapies for chronic wounds, neurodegenerative diseases, and rare disorders, in addition to their explorations into space health.

With the rapid pace of advancements in both space exploration and biomedicine, Energenesis remains at the forefront, blending technology and healthcare to tackle some of the most pressing challenges of human health in extreme environments. Their work promises to reshape not just space biomedicine but also advance treatments applicable here on Earth.